David Ginsburg
December 13, 2023

Life-changing Therapeutics

The U.S. Food and Drug Administration recently approved the first available therapeutic treatment for a rare, life-threatening genetic disorder. TAK-755, commercially known as Adzynma, was developed over the past two decades in the laboratory of U-M researcher David Ginsburg. This marks the seventh U-M invention that has secured FDA approval

Drs. Camper and Kitzman recently published an article in The American Journal of Human Genetics
July 28, 2021

An often overlooked cause of genetic disease

by Elisabeth Paymal | 07.28.2021

Often overlooked because they might not alter the amino acid production, splicing defects can play an important role in rare genetic pituitary gland diseases.